Triazine compounds as PI3 kinase and mTOR inhibitors

1. A method of treating a cancer selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, brain cancer, soft-tissue sarcoma, and bone sarcoma comprising administering to a mammal in need thereof a compound of the Formula I:

wherein:

R 1 is

wherein:

R 6 , R 7 , R 8 , R 9 are each independently selected from the group consisting of a hydrogen atom, and a C 1 -C 6 alkyl optionally substituted with C 2 -C 6 alkenyl, C 4 -C 6 alkadienyl, C 2 -C 6 alkynyl or C 4 -C 6 alkadiynyl;

or one of R 6 and R 7 or R 8 and R 9 , together with the carbon atoms to which they are attached form an optionally substituted 5-8 membered saturated or unsaturated ring containing 0, 1 or 2 atoms independently selected from O, NH and S;

the dashed line - - - - - represents an optional second bond;

R 2 is optionally substituted C 6 -C 14 aryl-NH—COR 3 , optionally substituted C 1 -C 9 heteroaryl-NH—COR 3 , —CH═CH—C 6 -C 10 aryl-NH—COR 3 or —CH═CH—C 1 -C 9 heteroaryl-NH—COR 3 ;

R 3 is OR 5 , NR 5 R 5 or NHR 5 ;

R 5 is independently selected from the group consisting of C 1 -C 6 alkyl, C 3 —C 6 alkenyl, C 3 -C 6 alkynyl, optionally substituted C 6 -C 10 aryl, C 1 -C 6 haloalkyl, optionally substituted C 1 -C 9 heteroaryl, C 1 -C 6 hydroxylalkyl-, C 3 -C 10 saturated or unsaturated mono or bicyclic C 3 -C 10 cycloalkyl optionally substituted with OH, NR 11 R 11 or 3-7 membered C 1 -C 6 heterocyclyl, and 3-10 membered saturated or unsaturated mono or bicyclic C 1 -C 9 heterocyclyl, with the proviso that three-membered cycloalkyl and heterocyclyl rings are saturated;

or two R 5 groups taken together with the nitrogen atom to which they are attached form a 3 to 8 membered ring system optionally substituted with C 1 -C 6 alkyl, which ring system is saturated or unsaturated and has, in addition to said nitrogen atom, 0 to 2 heteroatom ring members selected from O, S, S(O), S(O) 2 and NR 10 ;

R 10 is selected from the group consisting of H, C 1 -C 6 alkyl, —SO 2 (C 1 -C 6 alkyl), —COO(C 1 -C 6 alkyl), —CONH(C 1 -C 6 alkyl), —CON(C 1 -C 6 alkyl) 2 , —CO(C 1 -C 6 alkyl), and —SO 2 NHR 11 ;

R 11 is selected from the group consisting of H, C 1 -C 6 alkyl optionally substituted with OH, NR 11 R 11 or a 3-7 membered C 1 -C 6 heterocyclyl, —CO(C 1 -C 6 alkyl), optionally substituted C 6 -C 10 aryl, and optionally substituted C 1 -C 9 heteroaryl;

R 4 is selected from the group consisting of: a) C 1 -C 6 alkyl optionally substituted with: i) 3-10 membered C 1 -C 9 heterocyclyl optionally substituted with C 1 -C 6 alkyl-, ii) H 2 N—, iii) (C 1 -C 6 alkyl)NH—, iv) (C 1 -C 6 alkyl) 2 N—, v) NH(CH 2 ) a N(C 1 -C 6 alkyl) 2 wherein a is 2, 3 or 4, and vi) CHO, b) C 3 -C 6 alkenyl, c) C 3 -C 6 alkynyl, d) —O—C 1 -C 8 alkyl optionally substituted with —O—C 1 -C 8 alkyl, e) —O—C 3 -C 8 alkenyl, f) —O—C 3 -C 8 alkynyl, g) saturated or unsaturated mono or bicyclic C 3 -C 8 cycloalkyl, and h) saturated or unsaturated mono or bicyclic —O—C 3 -C 12 cycloalkyl, all the above optionally substituted with OH, NR 11 R 11 or a 3-7 membered C 1 -C 6 heterocyclyl optionally substituted with C 1 -C 6 alkyl-, provided that an OH or NR 11 R 11 is not directly bonded to a carbon atom that is double- or triple-bonded to another carbon atom; i) —CH═CH—C 6 -C 10 aryl; j) —CH═CH—C 1 -C 9 heteroaryl; k) optionally substituted C 6 -C 10 aryl; l) optionally substituted 5-10 membered C 1 -C 9 heteroaryl attached to the triazine moiety via a carbon atom; m) 3-10 membered saturated or unsaturated monocyclic C 1 -C 9 heterocyclyl attached to the triazine moiety through a carbon or nitrogen atom and optionally substituted with from 1 to 3 substituents independently selected from: OH, NR 11 R 11 , C 1 -C 6 alkyl, (C 1 -C 6 alkyl)amido-, (C 1 -C 6 alkyl)C(O)—, (C 1 -C 6 alkoxy)carbonyl-, adamantyl, C 1 -C 6 hydroxylalkyl-, (C 1 -C 6 alkyl)amido-; or a 3-7 membered C 1 -C 6 heterocyclyl, with the proviso that 3 membered heterocyclyl is saturated and attached to the triazine moiety through a nitrogen atom, and 5 membered bicyclic heterocyclyl is saturated; n) optionally substituted —O—C 6 -C 10 aryl; o) optionally substituted —O—C 1 -C 9 heteroaryl; p) —O-(3-12 membered saturated or unsaturated mono or bicyclic)C 1 -C 9 heterocyclyl optionally substituted with (C 1 -C 6 alkoxy)carbonyl-, H 2 NS(O) 2 —, or C 1 -C 6 alkyl further optionally substituted with OH, NR 11 R 11 or a 3-7 membered C 1 -C 6 heterocyclyl, with the proviso that three membered heterocyclyl is saturated; q) —NHC 6 -C 10 aryl, r) —NHC 1 -C 9 heteroaryl, s) —NHNH 2 , t) —NHNHC 1 -C 6 alkyl, u) —NHN(C 1 -C 6 alkyl) 2 , v) —NHOH, w) —COOH, x) —COO—C 1 -C 6 alkyl, y) —CONR 12 R 13 , z) —NR 12 R 13 ,

wherein Z is CH 2 , O, S(O) n or NR 10 and n is 0, 1 or 2;

ee) halogen, ff) C 6 -C 14 aryl-S(O) 2 —NH—, gg) R 11 NHC(O)NH—O—, and hh) optionally substituted 5-membered monocyclic C 1 -C 4 heteroaryl attached to the triazine moiety via a nitrogen atom;

R 12 and R 13 are each independently selected from H, optionally mono or disubstituted C 1 -C 8 alkyl, optionally substituted C 3 -C 8 alkenyl, and optionally substituted C 3 -C 8 alkynyl, the optional substituents being selected from C 1 -C 6 alkoxy, OH, NR 11 R 11 , and 3-7 membered C 1 -C 6 heterocyclyl, provided that an OH or NR 11 R 11 is not directly bonded to a carbon atom that is double- or triple-bonded to another carbon atom;

or R 12 and R 13 taken together with the nitrogen atom to which they are attached form a 3 to 8 membered monocyclic ring system optionally substituted with C 1 -C 6 alkyl, which ring system is saturated or unsaturated and has, in addition to said nitrogen atom, 0 to 2 heteroatom ring members selected from O, S(O) n and NR 10 ;

or R 12 and R 13 taken together with the nitrogen atom to which they are attached form

wherein a and b are each independently —CH 2 —, O, S, or NR 10 , and x is 1-3;

C 1 -C 9 heteroaryl refers to a 5-10 membered aromatic ring system having one or more rings and 1, 2, 3 or 4 ring members independently selected from O, NR 10 , and S(O) n ;

C 1 -C 9 heterocyclyl refers to a 3-10 membered ring system having one or more rings and 1, 2, 3 or 4 ring members independently selected from O, NR 10 , and S(O) n ; and

optionally substituted aryl and heteroaryl groups are unsubstituted or are substituted with 1 or 2 moieties selected from the group consisting of: a) C 1 -C 6 alkyl optionally substituted with OH, NH 2 , NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl) 2 , —NH(CH 2 ) w N(C 1 -C 6 alkyl) 2 wherein w is 2, 3 or 4, or 3-10 membered C 1 -C 9 heterocyclyl optionally substituted with from 1 to 3 independently selected C 1 -C 6 alkyl- substituents; b) halogen; c) hydroxy; d) NH 2 ; e) NO 2 ; f) SO 2 NH 2 ; g) COOH; h) COO(C 1 -C 6 alkyl); i) NHCOO(C 1 -C 6 alkyl); j) NH(C 1 -C 6 alkyl); k) N(C 1 -C 6 alkyl) 2 ; l) C(O)NR a R b , wherein R a is H or C 1 -C 6 alkyl, and R b is H, C 1 -C 6 alkyl, (C 6 -C 14 aryl)alkyl-, or (C 1 -C 9 heteroaryl)alkyl-; m) —Y-Q, wherein Y is: i) O, ii) NH, iii) N(C 1 -C 6 alkyl), iv) NHSO 2 , v) SO 2 NH, vi) NHCONH, vii) NHCON(C 1 -C 6 alkyl), viii) S(O) q , q is 0, 1 or 2, ix) —C(O)NH—, x) —NHC(O)— xi) —C(O)N(CH 3 )—, xii) C(O), or xiii) absent, and Q is selected from: i) C 6 -C 10 aryl, optionally substituted with from 1 to 3 substituents independently selected from: A) C 1 -C 6 alkoxy- optionally substituted with 1) H 2 N—, 2) (C 1 -C 6 alkyl)amino-, 3) di(C 1 -C 6 alkyl)amino-, 4) C 1 -C 9 heterocyclyl- optionally substituted by C 1 -C 6 alkyl-, or 5) hydroxyl, B) (C 1 -C 6 alkoxy)carbonyl-, C) (C 1 -C 6 alkoxy)C(O)NH—, D) C 1 -C 6 alkyl- optionally substituted with 1) H 2 N—, 2) (C 1 -C 8 alkyl)amino-, or 3) di(C 1 -C 6 alkyl)amino-, E) (C 1 -C 6 alkyl)amino-, F) di(C 1 -C 6 alkyl)amino-, G) (C 1 -C 6 alkyl)amido- optionally substituted with 1) H 2 N—, 2) (C 1 -C 6 alkyl)amino-, or 3) di(C 1 -C 6 alkyl)amino-, H) (C 1 -C 6 alkyl)carboxyamido-, I) C 1 —O 9 heterocyclyl- optionally substituted by C 1 -C 6 alkyl- or C 1 -C 6 hydroxylalkyl-, J) heterocyclyl(C 1 -C 8 alkyl)- optionally substituted by C 1 -C 6 alkyl-, K) halogen, L) hydroxyl, M) C 1 -C 6 hydroxylalkyl-, N) perfluoro(C 1 -C 6 )alkyl-, O) H 2 N—, P) O 2 N—, Q) H 2 NSO 2 —, R) HO 2 C—, and S) NC—, ii) 5-10 membered C 1 -C 9 heteroaryl, optionally substituted with from 1 to 3 substituents independently selected from: A) C 1 -C 6 alkoxy- optionally substituted with 1) H 2 N—, 2) (C 1 -C 6 alkyl)amino-, 3) di(C 1 -C 6 alkyl)amino-, 4) C 1 -C 9 heterocyclyl- optionally substituted by C 1 -C 6 alkyl-, or 5) hydroxyl, B) (C 1 -C 6 alkoxy)carbonyl-, C) (C 1 -C 6 alkoxy)C(O)NH—, D) C 1 —C 6 alkyl- optionally substituted with 1) H 2 N—, 2) (C 1 -C 6 alkyl)amino-, or 3) di(C 1 -C 6 alkyl)amino-, E) (C 1 -C 6 alkyl)amino-, F) di(C 1 -C 6 alkyl)amino-, G) (C 1 -C 6 alkyl)amido- optionally substituted with 1) H 2 N—, 2) (C 1 -C 6 alkyl)amino-, or 3) di(C 1 -C 6 alkyl)amino-, H) (C 1 -C 6 alkyl)carboxyamido-, I) C 1 -C 9 heterocyclyl- optionally substituted by C 1 -C 6 alkyl- or C 1 -C 6 hydroxylalkyl-, J) heterocyclyl(C 1 -C 6 alkyl)- optionally substituted by C 1 —C 6 alkyl-, K) halogen, L) hydroxyl, M) C 1 -C 6 hydroxylalkyl-, N) perfluoro(C 1 -C 6 )alkyl-, O) H 2 N—, P) O 2 N—, Q) H 2 NSO 2 —, R) HO 2 C—, and S) NC—, iii) 3-10 membered C 1 -C 9 heterocyclyl, optionally substituted with from 1 to 3 substituents independently selected from: A) C 1 -C 6 alkyl-, B) heterocyclyl(C 1 -C 6 alkyl)-, C) (C 6 -C 14 aryl)alkyl-, D) C 1 -C 8 acyl-, E) (C 1 -C 6 alkoxy)carbonyl-, F) (C 1 -C 6 alkyl)carboxyl-, G) halogen, H) C 1 -C 6 haloalkyl-, I) hydroxyl, J) C 1 -C 6 hydroxyalkyl-, K) H 2 N—, L) (C 1 -C 6 alkyl)amino-, M) di(C 1 -C 6 alkyl)amino-, N) HO 2 C—, O) (C 1 -C 6 alkoxy)carbonyl-, P) (C 1 -C 6 alkyl)carboxyl-, Q) (C 1 -C 6 alkyl)amido-, R) H 2 NC(O)—, S) (C 1 -C 6 alkyl)carboxyamido-, T) 5-10 membered C 1 -C 9 heteroaryl, U) C 6 -C 14 ary, V) C 3 -C 8 cycloalkyl W) 3-10 membered C 1 -C 9 heterocyclyl, X) NC—; and Y) —NO 2 ; iv) C 3 -C 10 cycloalkyl, v) C 1 -C 6 alkyl, vi) C 2 -C 6 alkenyl, vii) C 2 -C 6 alkynyl, viii) C 1 -C 6 hydroxyalkyl-, ix) (CH 2 ) v O(C 1 -C 6 alkyl), x) (CH 2 ) v NH 2 , xi) (CH 2 ) v NH(C 1 -C 6 alkyl), xii) (CH 2 ) v N(C 1 -C 6 alkyl) 2 , xiii) O(CH 2 ) v N(C 1 -C 6 alkyl) 2 , xiv) (CH 2 ) v C 6 -C 10 aryl, xv) —CN, xvi) (CH 2 ) v 5-10 membered C 1 -C 9 heteroaryl, xvii) (CH 2 ) v 3-10 membered C 1 -C 9 heterocyclyl, optionally substituted by C 1 -C 6 alkyl-, wherein v is 1, 2, 3 or 4, and xviii) C 1 -C 6 perfluoroalkyl-; and n) C(O)R c wherein R c is: i) H, ii) C 1 -C 6 alkyl, or iii) C 3 —C 6 cycloalkyl,

and pharmaceutically acceptable salts thereof, in an amount effective to treat the cancer.

2. The method of claim 1 , wherein said cancer is renal cell carcinoma.

3. The method of claim 1 , wherein said cancer is acute lymphoblastic leukemia.

4. The method of claim 1 , wherein said cancer is acute malignant melanoma.

5. A method of claim 1 wherein said cancer is soft-tissue or bone sarcoma.

6. A method of treating cancer selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, brain cancer, soft-tissue sarcoma, and bone sarcoma, comprising administering to a mammal in need thereof the compound 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, and pharmaceutically acceptable salts thereof, in an amount effective to treat the cancer.

7. The method of claim 1 wherein R 1 is

8. The method of claim 1 wherein R 2 is optionally substituted C 6 -C 14 aryl-NH—COR 3 .

9. The method of claim 1 wherein R 2 is optionally substituted phenyl-NH—COR 3 .

10. The method of claim 1 wherein R 3 is NHR 5 .